The peripheral cannabinoid receptor 1 antagonist VD60 efficiently inhibits carbon tetrachloride-intoxicated hepatic fibrosis progression

Wei, Yan; Kang, Xiao-li; Wang, Xu
February 2014
Experimental Biology & Medicine;Feb2014, Vol. 239 Issue 2, p183
Academic Journal
No abstract available.


Related Articles

  • CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Teixeira-Clerc, Fatima; Julien, Boris; Grenard, Pascale; Van Nhieu, Jeanne Tran; Deveaux, Vanessa; Li, Liying; Serriere-Lanneau, Valérie; Ledent, Catherine; Mallat, Ariane; Lotersztajn, Sophie // Nature Medicine;Jun2006, Vol. 12 Issue 6, p671 

    Hepatic fibrosis, the common response associated with chronic liver diseases, ultimately leads to cirrhosis, a major public health problem worldwide. We recently showed that activation of hepatic cannabinoid CB2 receptors limits progression of experimental liver fibrosis. We also found that...

  • Role of cannabinoids in chronic liver diseases. Parfieniuk, Anna; Flisiak, Robert; Weinman, Steven Alan // World Journal of Gastroenterology;10/28/2008, Vol. 14 Issue 40, p6109 

    Cannabinoids are a group of compounds acting primarily via CB1 and CB2 receptors. The expression of cannabinoid receptors in normal liver is low or absent. However, many reports have proven up-regulation of the expression of CB1 and CB2 receptors in hepatic myofibroblasts and vascular...

  • Watching the pot boil. Fields, Howard L.; Meng, Ian D. // Nature Medicine;Sep98, Vol. 4 Issue 9, p1008 

    Selective antagonists of the two cannabinoid receptors unveil distinct but synergistic peripheral analgesic activities for endogenous cannabinoids.

  • Cannabinoid Receptor Type I Modulates Alcohol-Induced Liver Fibrosis. Patsenker, Eleonora; Stoll, Matthias; Millonig, Gunda; Agaimy, Abbas; Wissniowski, Till; Schneider, Vreni; Mueller, Sebastian; Brenneisen, Rudolf; Seitz, Helmut K.; Ocker, Matthias; Stickel, Felix // Molecular Medicine;Nov/Dec2012, Vol. 17 Issue 11/12, p1285 

    The cannabinoid system (CS) is implicated in the regulation of hepatic fibrosis, steatosis and inflammation, with cannabinoid receptors 1 and 2 (CB1 and CB2) being involved in regulation of pro- and antifibrogenic effects. Daily cannabis smoking is an independent risk factor for the progression...

  • Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Izzo, A. A.; Camilleri, M. // Gut;Aug2008, Vol. 57 Issue 8, p1140 

    A multitude of physiological effects and putative pathophysiological roles have been proposed for the endogenous cannabinoid system in the gastrointestinal tract, liver and pancreas. These range from effects on epithelial growth and regeneration, immune function, motor function, appetite...

  • Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl4-induced advanced cirrhosis. Giannone, Ferdinando A; Baldassarre, Maurizio; Domenicali, Marco; Zaccherini, Giacomo; Trevisani, Franco; Bernardi, Mauro; Caraceni, Paolo // Laboratory Investigation (00236837);Mar2012, Vol. 92 Issue 3, p384 

    The endocannabinoid system is involved in the pathogenesis of liver fibrosis. Although many substances have been proved to reduce fibrosis in experimental models of chronic liver injury, most of them appear to be effective only if given as a prophylactic or early treatment. This study aimed to...

  • The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases. Tam, Joseph // Journal of Basic & Clinical Physiology & Pharmacology;May2016, Vol. 27 Issue 3, p267 

    Endocannabinoids (eCBs) are endogenous lipid ligands that bind to cannabinoid receptors that also mediate the effects of marijuana. The eCB system is comprised of eCBs, anandamide, and 2-arachidonoyl glycerol, their cannabinoid-1 and cannabinoid-2 receptors (CB1 and CB2, respectively), and the...

  • Suppression of CB1 Cannabinoid Receptor by Lentivirus Mediated Small Interfering RNA Ameliorates Hepatic Fibrosis in Rats. Si-Wen Chen; Ben-Yan Wu; Shi-Ping Xu; Ke-Xing Fan; Li Yan; Yuan Gong; Jun-Bao Wen; Dao-Hong Wu // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    It is recognized that endogenous cannabinoids, which signal through CB1 receptors in hepatic stellate cells (HSCs), exert a profibrotic effect on chronic liver diseases. In this study, we suppressed CB1 expression by lentivirus mediated small interfering RNA (CB1-RNAi-LV) and investigated its...

  • Bisdemethoxycurcumin Induces Apoptosis in Activated Hepatic Stellate Cells via Cannabinoid Receptor 2. Phil Jun Lee; Seung Je Woo; Jun-Goo Jee; Sang Hyun Sung; Hong Pyo Kim // Molecules;2015, Vol. 20 Issue 1, p1277 

    Activated Hepatic Stellate Cells (HSCs), major fibrogenic cells in the liver, undergo apoptosis when liver injuries cease, which may contribute to the resolution of fibrosis. Bisdemethoxycurcumin (BDMC) is a natural derivative of curcumin with anti-inflammatory and anti-cancer activities. The...

  • Kannabinoid Tip 1 Reseptör (CB1) ve Terapötik YaklaÅŸimlara Genel BakiÅŸ-II. Çinar, Özge Gündüz; Çinar, Reşat // Journal of Marmara University Institute of Health Sciences;Mar2012, Vol. 2 Issue 1, p1 

    Cannabinoid receptor 1 (CB1) is highly important in the pathophysiology of several diseases due to their regulatory roles in central nervous system and peripheral tissues. Direct use of cannabinoids is limited mostly because of their psychoactive properties; therefore augmenting endocannabinoids...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics